Antineoplastic effect of β-elemene on prostate cancer cells and other types of solid tumour cells

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 8, 2010, Pages 1018-1027

  Li, Qingdi Quentin ^a,b   Wang, Gangduo ^a   Huang, Furong ^a   Banda, Malathi ^a   Reed, Eddie ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

elemene; apoptosis; caspases; Chinese medicine; natural product; prostate cancer

Indexed keywords

ANDROGEN; BETA ELEMENE; CASPASE 10; CASPASE 3; CASPASE 7; CASPASE 9; CYTOCHROME C; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROPIDIUM IODIDE; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BRAIN CANCER; BREAST CARCINOMA; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CARCINOMA CELL; CELL DEATH; CELL TYPE; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME RELEASE; FEMALE; FLOW CYTOMETRY; HORMONE RESISTANCE; HUMAN; HUMAN CELL; IC 50; LUNG CARCINOMA; MALE; MITOSIS INHIBITION; NICK END LABELING; PROSTATE CARCINOMA; SOLID TUMOR; STAINING; TUMOR CELL; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING;

ANNEXIN A5; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; BRAIN NEOPLASMS; BREAST NEOPLASMS; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLONIC NEOPLASMS; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IN SITU NICK-END LABELING; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MALE; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; SESQUITERPENES; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 77954936163     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01135.x     Document Type: Article

References (66)

1. US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2005 Incidence and Mortality Web-based Report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute. 2009. Available at: http://www.cdc.gov/uscs.
2. Isaacs JT et al. The role of androgen in the regulation of programmed cell death/apoptosis in normal and malignant prostatic tissue. Semin Cancer Biol 1994 5 : 391 400.
3. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol 1997 79 : 235 246.
4. Mohler JL. Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol 2008 617 : 223 234.
5. Dutt SS, Gao AC. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol 2009 5 : 1403 1413.
6. Mostaghel EA et al. Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease. Urol Oncol 2009 27 : 251 257.
7. Attar RM et al. Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 2009 15 : 3251 3255.
8. Chi KN et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 2009 56 : 594 605.
9. Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002 60 : 132 138.
10. Holzbeierlein J et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004 164 : 217 227.
11. Montgomery RB et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008 68 : 4447 4454.
12. Meulenbeld HJ et al. Chemotherapy in patients with castration-resistant prostate cancer. Eur J Cancer. 2009 45 : 161 171.
13. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000 14 : 2410 2434.
14. Wang G, Reed E, Li QQ. Apoptosis in prostate cancer: progressive and therapeutic implications (Review). Int J Mol Med 2004 14 : 23 34.
15. Cryns V, Yuan J. Proteases to die for. Genes Dev 1998 12 : 1551 1570.
16. Johnstone RW et al. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002 108 : 153 164.
17. Lassus P et al. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 2002 297 : 1352 1354.
18. Rokhlin OW et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997 57 : 1758 1768.
19. Chen YWX. β-Elemene method to prepare the same and use thereof. US 6464839. 2002.
20. Chen A. Elemene compositions containing liquid oil. US 0186230. 2005.
21. Huang L. Synthesis of β-elemene intermediates thereto, analogues and uses thereof. US 0014987. 2006.
22. Zheng S et al. Initial study on naturally occurring products from traditional Chinese herbs and vegetables for chemoprevention. J Cell Biochem 1997 27 : 106 112.
23. Zhou H et al. Experimental study on apoptosis induced by elemene in glioma cells. Ai Zheng 2003 22 : 959 963.
24. Wang G et al. Antitumor effect of β-elemene in non-small-cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell Mol Life Sci 2005 62 : 881 893.
25. Li X et al. Antiproliferative effect of β-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase. Cell Mol Life Sci 2005 62 : 894 904.
26. Zhao J et al. In vitro combination characterization of the new anticancer plant drug b-elemene with taxanes against human lung carcinoma. Int J Oncol 2007 31 : 241 252.
27. Li QQ et al. β-Elemene, a novel plant-derived antineoplastic agent, increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis. Oncol Rep 2009 22 : 161 170.
28. Wu XS et al. An investigation of the ability of elemene to pass through the blood-brain barrier and its effect on brain carcinomas. J Pharm Pharmacol 2009 61 : 1653 1656.
29. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994 78 : 539 542.
30. Wang HQ et al. Epidermal growth factor receptor-dependent, NF-kB-independent activation of the phosphatidylinositol 3-kinase/Akt pathway inhibits ultraviolet irradiation-induced caspases-3, -8, and -9 in human keratinocytes. J Biol Chem 2003 278 : 45737 45745.
31. Kim HS et al. Insulin-like growth factor-binding protein 3 induces caspase-dependent apoptosis through a death receptor-mediated pathway in MCF-7 human breast cancer cells. Cancer Res 2004 64 : 2229 2237.
32. Negoescu A et al. In situ apoptotic cell labeling by the TUNEL method: improvement and evaluation on cell preparations. J Histochem Cytochem 1996 44 : 959 968.
33. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998 281 : 1312 1316.
34. Zou H et al. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999 274 : 11549 11556.
35. Bell C, Hawthorne S. Ellagic acid, pomegranate and prostate cancer - a mini review. J Pharm Pharmacol 2008 60 : 139 144.
36. Albrecht M et al. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J Med Food 2004 7 : 274 283.
37. Malik A et al. Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. Proc Natl Acad Sci USA 2005 102 : 14813 14818.
38. Malik A, Mukhtar H. Prostate cancer prevention through pomegranate fruit. Cell Cycle 2006 5 : 371 373.
39. Bemis DL et al. Clinical trials of natural products as chemopreventive agents for prostate cancer. Expert Opin Investig Drugs 2006 15 : 1191 1200.
40. Busby JE, Kamat AM. Chemoprevention for bladder cancer. J Urol 2006 176 : 1914 1920.
41. Kumar N et al. Green tea polyphenols in the prevention of colon cancer. Front Biosci 2007 12 : 2309 2315.
42. Zhu YS et al. The Chinese medicinal herbal formula ZYD88 inhibits cell growth and promotes cell apoptosis in prostatic tumor cells. Oncol Rep 2003 10 : 1633 1639.
43. Liang G et al. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. Int J Oncol 2010 37 : 111 123.
44. Fisher D. Apoptosis in cancer therapy: crossing the threshold. Cell 1994 78 : 539 542.
45. Huang H et al. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 2001 276 : 38830 38836.
46. Morris MJ, Scher HI. Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer 2000 89 : 1329 1348.
47. Gardner TA et al. Prostate cancer gene therapy: past experiences and future promise. Cancer Metastasis Rev 2002 21 : 137 145.
48. Wang JL et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A 2000 97 : 7124 7129.
49. Reed JC. Mechanisms of apoptosis. Am J Pathol 2000 157 : 1415 1430.
50. Gross A et al. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999 13 : 1899 1911.
51. Morrissey C et al. Apigenin drives the production of reactive oxygen species and initiates a mitochondrial mediated cell death pathway in prostate epithelial cells. Prostate 2005 63 : 131 142.
52. Vilenchik M et al. Antisense RNA down-regulation of bcl-xL expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents. Cancer Res 2002 62 : 2175 2183.
53. Catz SD, Johnson JL. BCL-2 in prostate cancer: a minireview. Apoptosis 2003 8 : 29 37.
54. McDonnell TJ et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992 52 : 6940 6944.
55. McConkey DJ et al. Apoptosis resistance increases with metastatic potential in cells of the human LNCaP prostate carcinoma line. Cancer Res 1996 56 : 5594 5599.
56. Mackey TJ et al. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology 1998 52 : 1085 1090.
57. Pollack A et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer 2003 97 : 1630 1633.
58. Saleh A et al. Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation. J Biol Chem 1999 274 : 17941 17945.
59. Adams JM, Cory S. Apoptosomes: engines for caspase activation. Curr Opin Cell Biol 2002 14 : 715 720.
60. Hengartner MO. The biochemistry of apoptosis. Nature 2000 407 : 770 776.
61. Krajewska M et al. Immunohistochemical analysis of in vivo patterns of expression of CPP32 (Caspase-3), a cell death protease. Cancer Res 1997 57 : 1605 1613.
62. Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res 2003 63 : 4713 4723.
63. Kumi-Diaka J et al. The mediating role of caspase-3 protease in the intracellular mechanism of genistein-induced apoptosis in human prostatic carcinoma cell lines, DU145 and LNCaP. Biol Cell 2000 92 : 595 604.
64. Marcelli M et al. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res 1999 59 : 382 390.
65. Coffey RN et al. Priming prostate carcinoma cells for increased apoptosis is associated with up-regulation of the caspases. Cancer 2001 92 : 2297 2308.
66. Duriez PJ, Shah GM. Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol 1997 75 : 337 349.